Lymphoma
Phase II
Accepting Patients
nct/study# NCT03113500 / COH-17058
A Phase 2 Study Of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, And Prednisone (CHEP-BV) Followed By BV Consolidation In Patients With CD30-Positive Peripheral T-Cell Lymphomas
Learn More
Lymphoma
Phase II
Accepting Patients
nct/study# NCT03712202 / COH18157
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin And Nivolumab Incorporated And Radiation Free Management Of Early Stage Classical Hodgkin Lymphoma (Chl)
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT03952078 / CPI-818-001
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, An Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, In Subjects With Relapsed/Refractory T-Cell And Follicular B-Cell Non-Hodgkin Lymphoma
Learn More
Lymphoma
Phase III
Accepting Patients
nct/study# NCT02972840 / ACE-LY-308
A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study Of Bendamustine And Rituximab (BR) Alone Versus In Combination With Acalabrutinib (ACP 196) In Subjects With Previously Untreated Mantle Cell Lymphoma
Learn More
Lymphoma
Phase I/II
Accepting Patients
nct/study# NCT03218683 / D6910C00001
A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study To Assess The Safety, Tolerability, Pharmacokinetics And Preliminary Antitumor Activity Of Ascending Doses Of AZD5991 In Subjects With Relapsed Or Refractory Haematologic Malignancies
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NCT03816683 / D8220R00004
Astrazeneca/ Treatment Patterns, Outcomes, And Patient-Reported Health-Related Quality Of Life: A Prospective Disease Registry Of Patients With Mantle Cell Lymphoma Treated With Novel Agents
Learn More
